Aviso Wealth Management Has $2.11 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Aviso Wealth Management boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 113.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,414 shares of the medical research company's stock after buying an additional 1,818 shares during the quarter. Thermo Fisher Scientific makes up 1.1% of Aviso Wealth Management's investment portfolio, making the stock its 20th largest holding. Aviso Wealth Management's holdings in Thermo Fisher Scientific were worth $2,112,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of TMO. Signature Resources Capital Management LLC lifted its position in Thermo Fisher Scientific by 318.2% in the second quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company's stock valued at $25,000 after purchasing an additional 35 shares during the last quarter. Peterson Financial Group Inc. bought a new position in shares of Thermo Fisher Scientific in the third quarter worth about $27,000. New Millennium Group LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter worth about $29,000. Stephens Consulting LLC grew its position in shares of Thermo Fisher Scientific by 116.0% during the second quarter. Stephens Consulting LLC now owns 54 shares of the medical research company's stock worth $30,000 after purchasing an additional 29 shares in the last quarter. Finally, Bank & Trust Co purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth approximately $33,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the transaction, the executive vice president now directly owns 16,663 shares in the company, valued at approximately $9,333,946.08. This represents a 1.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 9,000 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $552.86, for a total value of $4,975,740.00. Following the completion of the sale, the chief executive officer now directly owns 14,608 shares in the company, valued at $8,076,178.88. This represents a 38.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 37,150 shares of company stock valued at $20,651,865 in the last ninety days. 0.34% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have weighed in on TMO shares. UBS Group upgraded Thermo Fisher Scientific to a "strong-buy" rating in a research note on Monday, September 16th. Wells Fargo & Company reduced their target price on Thermo Fisher Scientific from $670.00 to $660.00 and set an "overweight" rating for the company in a report on Thursday, October 24th. Evercore ISI dropped their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an "outperform" rating for the company in a research report on Thursday, October 24th. Raymond James raised their price objective on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an "outperform" rating in a report on Thursday, July 25th. Finally, Bank of America lifted their price objective on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a "buy" rating in a report on Monday, September 16th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $649.33.

Thermo Fisher Scientific Trading Down 2.4 %

TMO traded down $12.47 on Monday, hitting $500.61. The company had a trading volume of 1,878,645 shares, compared to its average volume of 1,476,028. The company has a market cap of $191.48 billion, a PE ratio of 32.17, a PEG ratio of 3.39 and a beta of 0.79. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The business's fifty day simple moving average is $586.43 and its 200 day simple moving average is $582.39. Thermo Fisher Scientific Inc. has a 12-month low of $465.90 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping analysts' consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. Thermo Fisher Scientific's revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.69 earnings per share. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.67 EPS for the current year.

Thermo Fisher Scientific announced that its Board of Directors has approved a share buyback program on Friday, November 15th that allows the company to buyback $4.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 2% of its stock through open market purchases. Stock buyback programs are often a sign that the company's management believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.31%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.78%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.